LBF20207PG26: Difference between revisions
No edit summary |
No edit summary |
||
Line 13: | Line 13: | ||
|Symbol=15-KETO-PGF2<FONT FACE="Symbol">a</FONT> | |Symbol=15-KETO-PGF2<FONT FACE="Symbol">a</FONT> | ||
|Biological Activity=It is well known that the biological activities of various prostaglandins are reduced upon their dehydrogenation at carbon-15 by the catalysis of 15-hydroxyprostaglandin dehydrogenase [[Reference:Anggard_E:,Acta Physiol. Scand.,1966,66,509|{{RelationTable/GetFirstAuthor|Reference:Anggard_E:,Acta Physiol. Scand.,1966,66,509}}]]. | |Biological Activity=It is well known that the biological activities of various prostaglandins are reduced upon their dehydrogenation at carbon-15 by the catalysis of 15-hydroxyprostaglandin dehydrogenase [[Reference:Anggard_E:,Acta Physiol. Scand.,1966,66,509|{{RelationTable/GetFirstAuthor|Reference:Anggard_E:,Acta Physiol. Scand.,1966,66,509}}]]. | ||
|Genetic Information=cDNA for placental 15-hydroxyprostaglandin dehydrogenase was cloned [[Reference:Ensor_CM:Tai_HH:,J. Lipid Mediat. Cell Signal.,1995,12,313|{{RelationTable/GetFirstAuthor|Reference:Ensor_CM:Tai_HH:,J. Lipid Mediat. Cell Signal.,1995,12,313}}]]. | |||
}} | }} | ||
{{Lipid/Footer}} | {{Lipid/Footer}} |
Revision as of 17:00, 27 January 2010
LipidBank Top (トップ) |
Fatty acid (脂肪酸) |
Glycerolipid (グリセロ脂質) |
Sphingolipid (スフィンゴ脂質) |
Journals (雑誌一覧) |
How to edit (ページの書き方) |
IDs and Links | |
---|---|
LipidBank | XPR1511 |
LipidMaps | LMFA03010026 |
CAS | |
KEGG | {{{KEGG}}} |
KNApSAcK | {{{KNApSAcK}}} |
mol | LBF20207PG26 |
15-KETOPROSTAGLANDIN F_2α | |
---|---|
Structural Information | |
7- [ 3 (R) ,5 (S) -Dihydroxy-2 (R) - (3-oxo-1 (E) -octenyl) cyclopentan-1 (R) -yl ] -5 (Z) -heptenoic acid | |
| |
15-KETO-PGF2a | |
Formula | C20H32O5 |
Exact Mass | 352.224974134 |
Average Mass | 352.46508 |
SMILES | C(CCC(=O)C=C[C@H]([C@H]1CC=CCCCC(O)=O)[C@@H](C[C@@H]1O)O)CC |
Physicochemical Information | |
15-Keto-prostaglandin F2a is the oxidized product of prostaglandin F2a by 15-hydroxyprostaglandin dehydrogenase, which is present in lung, kidney, placenta and other tissues and catalyzes the NAD- or NADP-dependent dehydrogenation of 15-dydroxyl group Hansen_HS . | |
15-Keto-prostaglandin F2a is further metabolized by its D13-reduction, b-oxidation and w oxidation. The ultimate metabolite is 5a,7a-dihydroxy-11-keto-tetranorprosta-1,16-dioic acid, and excreted in urine Granstrom_E et al.. | |
It is well known that the biological activities of various prostaglandins are reduced upon their dehydrogenation at carbon-15 by the catalysis of 15-hydroxyprostaglandin dehydrogenase Anggard_E . | |
cDNA for placental 15-hydroxyprostaglandin dehydrogenase was cloned Ensor_CM et al.. | |
Spectral Information | |
Mass Spectra | |
UV Spectra | |
IR Spectra | |
NMR Spectra | |
Other Spectra | |
Chromatograms |
Reported Metabolites, References | |||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|